Adrenocortical Carcinoma Clinical Trial
— PAXOOfficial title:
Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy
The study is designed as a Phase II, prospective, non randomized, open-label, single arm, multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to complete surgical resection and progressing to cytotoxic chemotherapy will receive Sorafenib plus metronomic chemotherapy as treatment.The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in patients with locally advanced or metastatic ACC who progressed after first or second line chemotherapy.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | October 2010 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Histologically confirmed diagnosis of ACC - Locally advanced or metastatic disease not amenable to radical surgery resection - Radiologically monitorable disease - Progressing disease after one or two cytotoxic chemotherapy regimens (including a platin-based protocol) - ECOG performance status 0-2 - Life expectancy = 3 months - Subjects with at least one uni-dimensional(for RECIST) or bi-dimensional(for WHO) measurable lesion. Lesions must be measured by CT-scan or MRI - Age = 18 years - Adequate bone marrow reserve (neutrophils = 1500/mm³ and platelets = 80.000/mm³) - Hemoglobin > 9.0 g/dl - Total bilirubin < 1.5 times the upper limit of normal - PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.] - Serum creatinine < 1.5 x upper limit of normal - Effective contraception in pre-menopausal female and male patients - Patient´s written informed consent - Ability to comply with the protocol procedures Exclusion criteria: - History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years. - History of HIV infection or chronic hepatitis B or C (This criteria should be modified to allow Hepatitis B or C in protocols looking at HCC patient population) - Active clinically serious infections (> grade 2 NCI-CTC version 3.0) - Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry) - Patients with seizure disorder requiring medication (such as steroids or anti-epileptics) - History of organ allograft The organ allograft may be allowed as protocol specific - Severe renal (serum creatinine > 2.5 x ULN) or hepatic insufficiency (ALT / - AST > 2.5 x ULN or ALT/AST >5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin > 2.5 x ULN) - Concomitant Rifampicin - Concomitant St. John's Wort (Hypericum perforatum) - Warfarin is allowed; however, close monitoring of Prothrombin Time (PT) is recommended - Decompensated heart failure (ejection fraction <45%), myocardial infarction or revascularization procedure during the last 6 months, unstable angina pectoris, uncontrolled cardiac arrhythmia - Hypertension that cannot be controlled by medications (>160/100 mmHg despite optimal medical therapy) - Patients with recent or active bleeding diathesis - Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. - Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and three months after the completion of trial - Previous treatment with Sorafenib or other anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry - Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed). - Major surgery within 4 weeks of start of study - Autologous bone marrow transplant or stem cell rescue within 4 months of study - Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study] - Current treatment with another investigational drug - Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Department of Clinical and Biological Sciences, University of Turin | Orbassano | |
Italy | Azienda Ospedaliera di Padova | Padova | |
Italy | Azienda Ospedaliera Università di Palermo | Palermo | |
Italy | Policlinico Universitario Campus Biomedico- Roma | Roma | |
Italy | Ist. Clin.Humanitas | Rozzano |
Lead Sponsor | Collaborator |
---|---|
University of Turin, Italy |
Italy,
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007 Jun 7;356(23):2372-80. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease free survival | 4 months | No | |
Secondary | Overall survival | 4 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04373265 -
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
|
Phase 1 | |
Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
Recruiting |
NCT06066333 -
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
|
Phase 2 | |
Recruiting |
NCT03127774 -
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
|
Phase 2 | |
Completed |
NCT01048892 -
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
|
Phase 1 | |
Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
Recruiting |
NCT05999292 -
Phase 1 Study of 68Ga-R8760
|
Phase 1 | |
Completed |
NCT05361083 -
First-in-human Evaluation of [18F]CETO
|
Early Phase 1 | |
Recruiting |
NCT05660889 -
Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
|
||
Completed |
NCT00003038 -
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|
||
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Enrolling by invitation |
NCT05036434 -
Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma
|
Phase 2 | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
Withdrawn |
NCT00469469 -
Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma
|
Phase 2 | |
Completed |
NCT00002608 -
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05839886 -
The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
|
||
Recruiting |
NCT05634577 -
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
|
Phase 2 |